Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 August 2007, Vol. 110, No. 3, pp. 799-805.
Prepublished online as a Blood First Edition Paper on April 5, 2007; DOI 10.1182/blood-2006-11-019265.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-11-019265v1
110/3/799    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, L. F.
Right arrow Articles by Zhang, D.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, L. F.
Right arrow Articles by Zhang, D.-E.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW ARTICLE

Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts

Luke F. Peterson1, Anita Boyapati1, Eun-Young Ahn1, Joseph R. Biggs1, Akiko Joo Okumura1, Miao-Chia Lo1, Ming Yan1, and Dong-Er Zhang1

1 Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA


   Abstract
Top
 Abstract
Introduction
 Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
 Future directions
 Authorship
 References
 
Nonrandom and somatically acquired chromosomal translocations can be identified in nearly 50% of human acute myeloid leukemias. One common chromosomal translocation in this disease is the 8q22;21q22 translocation. It involves the AML1 (RUNX1) gene on chromosome 21 and the ETO (MTG8, RUNX1T1) gene on chromosome 8 generating the AML1-ETO fusion proteins. In this review, we survey recent advances made involving secondary mutational events and alternative t(8;21) transcripts in relation to understanding AML1-ETO leukemogenesis.


   Introduction
Top
 Abstract
 Introduction
Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
 Future directions
 Authorship
 References
 
Acute myeloid leukemia (AML) is a heterogeneous disease that is classified based on the presence of specific cytogenetic abnormalities as well as the French-American-British (FAB) classification of the leukemic cells and immunophenotype. One of the common translocations identified in leukemia is between chromosome 8q22 and chromosome 21q22 (Figure 1a).1 It is associated with nearly 40% of cases of FAB-M2 AML and 8% to 20% of all cases of AML depending on the genetic background and geographic location of the population. The (8;21) translocation is also observed in approximately 6% of AML M1 and, more rarely, in AML M0, M4, M5, and other myeloproliferative syndromes.2,3 The involved genes are, on chromosome 8, MTG8 or ETO, meaning myeloid translocation gene or eight twenty-one, respectively,4,5 and AML1 (acute myeloid leukemia factor 1) on chromosome 21.4 The commonly used name for the t(8;21) fusion protein is AML1-MTG8 or AML1-ETO, and we refer to it as AML1-ETO in this review. AML1 was also discovered from other studies that are not related to t(8;21) and has several different names.6 Its HUGO (Nomenclature Committee of the Human Genome Organization) name is RUNX1. In correlation, MTG8/ETO is named RUNX1T1 for RUNX1 translocation 1.


Figure 1
View larger version (27K):
[in this window]
[in a new window]

  		Figure 1. The 8;21 chromosomal translocation. (A) A chromosome preparation of a t(8;21) patient depicting normal chromosome 8, a shorter chromosome 8 with the translocated chromosome 21 (left arrow), normal chromosome 21, and a longer chromosome 21 fused to the portion of chromosome 8 (right arrow). The image was kindly provided by Dr Janet Rowley. (B) Genomic structure of t(8;21). Depicted are the exons of both AML1 and ETO organized following the reciprocal translocation. The first 5 exons of AML1 are fused to exons 2 through 11 of ETO. P1 and P2 with the horizontal arrows denote the start sites of transcription based on the usage of the distal (P1) or proximal (P2) promoters of AML1. The reciprocal ETO-AML1 fusion shows exons 1b and 1a of ETO fused to exons 6 through 12 of AML1. Filled boxes and blank boxes indicate translated and untranslated exon sequences, respectively. (C) Protein structure of AML1-ETO. As explained in the text, the commonly known full-length AML1-ETO protein is a 752-amino acid protein. The N-terminal portion of AML1 up to its runt homology domain (RHD) is fused to most of the ETO protein. Shown are the regions of homology to the Drosophila Nervy protein (NHR1 to NLH4) and 3 proline-serine-threonine-rich (PST) regions. The vertical arrow points to the fusion junction between AML1 and ETO.

 
The t(8;21) generates the 2 fusion genes AML1-ETO and ETO-AML1 (Figure 1B). AML1-ETO mRNA is easily detectable using polymerase chain reaction (PCR) primers on 2 sides of the fusion point. However, ETO-AML1 mRNA was not identified using a similar approach (E. Kanbe, D.-E.Z., unpublished data, February 2003). This result indicates that the ETO-AML1 transcript is not expressed, is expressed at an extremely low level, or is highly unstable due to degradation. All of the studies on t(8;21) have therefore focused on AML1-ETO.

Most of the coding region of the ETO gene is fused to the AML1 amino terminus containing the DNA-binding runt homology domain (RHD) to generate an AML1-ETO fusion protein (Figure 1C).4,5,7 The ETO gene has 14 exons. The original cloned AML1-ETO cDNA contained ETO exons 2 through 11; the fusion transcript produces an AML1-ETO protein of 752 amino acids (Figure 1C).8 The ETO portion of the full-length AML1-ETO protein contains 3 proline-serine-threonine (PST)-rich regions and 4 Nervy homology regions (NHR1-4) (Figure 1C).9 The PST-rich regions have multiple potential kinase phosphorylation sites (SP [Serine-Proline] and TP [Threonine-Proline]). Phosphorylation of ETO has been reported although no kinase involved in its phosphorylation has been identified.10 NHR1, also called the TAF (TATA box binding protein associated factor) homology domain, shares a sequence similarity with TAF110 and other related TAFs. NHR2 has a hydrophobic amino acid heptad repeat, which is critical for ETO oligomerization.11 NHR3 contains a predicted coiled-coil structure. NHR4 is a myeloid-Nervy-DEAF1 (MYND) homology domain with 2 predicted zinc finger motifs.

Expression of the AML1-ETO fusion gene is under the control of the AML1 promoter. The AML1 gene has 2 promoters, the P1 (distal) and the P2 (proximal) promoters,12 whose arrangement is conserved in human, mouse, and zebrafish.13 The protein encoded by the transcript from the P1 promoter is 27 amino acids longer at the N terminus than the protein encoded by the P2 transcript. Studies of alternate AML1 promoter usage have been limited, but it is known that transcripts originating from P1 are present in day 7, 11, 15, and 17 of mouse embryos, but transcripts originating from P2 are only detectable at day 7.14 Differences are also observed when embryonic stem (ES) cells undergo hematopoietic differentiation in vitro.14 The P1 promoter was shown to be the major one used in hematopoietic stem cells and T cells.15 The published AML1-ETO cDNA originated from the AML1 P2 promoter.8 AML1-ETO transcripts originating from the P1 promoter transcripts have not yet been identified, and it still remains to be determined if such a transcript has complete functional similarity to the P2-derived transcript.

The consequences of AML1-ETO expression on cell biologic processes in both cell line and primary models have been extensively reviewed.9,16–18 Overall, its role in blocking cell cycle and promoting apoptosis contradicts its function in promoting leukemogenesis. However, AML1-ETO blocks myeloid, lymphoid, and erythroid differentiation in many of these models. Furthermore, a role of AML1-ETO in positively influencing stem cell renewal in primary human and murine hematopoietic stem cells and cell line models has been uncovered that relies on direct or indirect gene regulation of factors involved in stem cell maintenance. A recent review by Elagib and Goldfarb17 surveyed AML1-ETO's molecular role in regulating stem renewal and blocking hematopoietic differentiation, including interactions with various lineage-specific transcription factors, histone deacetylases, and methylases. Therefore, this review addresses AML1-ETO mouse models, the requirement and identification of additional point mutations, and the identified splice variant(s) of AML1-ETO.


   Additional mutations and mouse models of t(8;21) leukemogenesis
Top
 Abstract
 Introduction
 Additional mutations and mouse...
Transcribed isoforms of t(8;21)...
 Future directions
 Authorship
 References
 
In t(8;21) AML patient cells, 1 allele of AML1 and 1 allele of ETO are still normal. Furthermore, the AML1-ETO fusion gene is under the control of AML1 regulatory elements. However, all heterozygous AML1-ETO knock-in mice die around 12.5 days of embryogenesis and fail to establish definitive hematopoiesis.19,20 These major phenotypes are identical to those reported in homozygous AML1-deficient mice,21,22 indicating that AML1-ETO may dominantly block AML1 function during early embryo development.

To circumvent early embryo lethality, several other AML1-ETO transgenic mouse models have been established by different procedures, including tetracycline regulatable,23 myeloid lineage-specific MRP8 promoter directed,24 hematopoietic stem cell Sca-1 locus,25 and Cre recombinase-mediated conditional AML1-ETO expression transgenic mice.26,27 Except for mice with the Sca-1 locus-directed AML1-ETO expression, all of these transgenic mice remained healthy with normal hematopoiesis during their life span. Mice with AML1-ETO expression by the Sca-1 locus developed a myeloproliferative disorder with a latency of 6 months and a penetrance of 82% at 14 months following skin lesion epidermal hyperplasia as early as 4 weeks of age with hyperkeratosis and ulceration at older age.25 Interestingly, similar skin lesions around the eyes were observed in chimeras of AML1-ETO knock-in mice (L. Liu, D-E.Z., unpublished data, March 1997). Furthermore, virally transduced AML1-ETO expression and bone marrow transplantation approaches were also not able to induce leukemia development in recipient mice.28,29 However, abnormal expansion of hematopoietic early progenitors and extension of the life span of hematopoietic cells without leukemogenesis were noticed in these last models. Thus, the Sca-1 model and the retroviral approaches demonstrate that targeting of the right progenitor and/or stem cells is important for establishing a role of AML1-ETO in self-renewal biology. Furthermore, these models suggest that AML1-ETO may alter the epigenetic environment of stem cells, without causing acute leukemia, dependent on its ability to interact with histone deacetylases and methylases. However, the treatment of MRP8-AML1-ETO transgenic or conditional AML1-ETO knock-in mice with the DNA alkylation mutagen N-ethyl-N-nitrosourea (ENU) produced AML in more than 50% of the MRP8-AML1-ETO mice,24 while 31% of the conditional AML1-ETO mice developed granulocytic sarcoma that is commonly observed in t(8;21) patients.27 Thus, these results provided direct evidence that AML1-ETO is critical for causing myeloid leukemia, requiring one or more additional mutations for leukemogenesis.

The nature of additional mutations in patients associated with AML1-ETO-mediated leukemogenesis is evidenced by additional cytogenetic abnormalities such as the loss of one of the sex chromosomes.30 As shown in Table 1, 35% of female t(8;21) AML patients are missing one X chromosome and 56% of male t(8;21) AML patients lack the Y chromosome. Although loss of the sex chromosomes is a natural phenomenon associated with aging, the loss of sex chromosomes tends to occur at a significantly younger age and at a much higher frequency in patients with t(8;21) AML than in the general population.50 Furthermore, sex chromosome loss in other types of AML occurs in less than 5% of patients.31,50 These statistics suggest that the loss of certain sex chromosome genes may cooperate with t(8;21) in AML development. Furthermore, trisomy 8, trisomy 4, and chromosome 9 deletion are also associated with t(8;21) AML (Table 1). In addition to cytogenetic abnormalities, mutations of growth factor receptors, protooncogenes, and transcription factors are also identified in t(8;21) AML, which include stem cell factor receptor (c-KIT), FMS-related tyrosine kinase 3 (FLT3), N-RAS, PU.1, and AML1 (Table 1). Other chromosome translocations related to the development of myeloid proliferation diseases, such as t(5;12) (encoding the TEL-PDGFRß fusion protein) and t(9;22) (encoding the BCR-ABL fusion protein), are also reported in a few t(8;21) AML patients.51,52 The finding of activating mutations in kinases involved in leukemia associated with t(8;21), such as c-KIT and FLT3-ITD, impacts future cytogenic and mutagenic data collection from patients by molecular methods at presentation, thereby facilitating individual patient-directed chemotherapeutic treatments. This is exemplified by the possible use of imatinib in the case of the c-KIT N822K mutation46 or, in the case of c-KIT D816 mutations, the SRC/ABL inhibitor dasatinib53 or nilotinib,54,55 an ABL tyrosine kinase inhibitor. In the case of FLT3 mutants possibly combining treatments with FLT3-specific inhibitors such as PKC41256–58 or sunitinib.59,60


View this table:
[in this window]
[in a new window]

  		Table 1. Cytogenetic abnormalities and gene mutations associated with t(8; 21) leukemia

 
Using a mouse retroviral-mediated transduction bone marrow transplantation model, it has been shown that AML1-ETO cooperates with the oncogenic factors TEL-PDGFRß or the FLT3 internal duplication (FLT3/ITD).38,61 Two other recently reported mouse leukemia models with AML1-ETO include the expression of AML1-ETO in blood cells without IRF8 and the coexpression of AML1-ETO with Wilms tumor gene WT1.29,62 Both of these genes have been implicated in AML by loss and gain of expression, respectively. An increase of the cell cycle inhibitor p21WAF1 has been reported in AML1-ETO-expressing cells,63 suggesting a role in t(8;21)-related leukemogenesis. Interestingly, AML1-ETO induced leukemia in p21WAF1-deficient mouse bone marrow cells,64 suggesting that the bypass of pathways induced by the fusion protein itself may be another mechanism of AML1-ETO leukemogenesis.

Taken together, studies with AML1-ETO mouse models and the observed cytogenic and mutagenic events in patients fully support the notion that AML1-ETO is a critical factor but is not sufficient for leukemogenesis. In addition, the observation of the t(8;21) aberration still being detected after remission in a patient that contained both t(8;21) and an activating mutant of c-KIT suggests that the chromosomal translocation is the first event.46 Furthermore, AML1-ETO is often detected in remission patients, suggestive of minimal residual disease. Further evidence that the translocation occurred in stem cells comes from AML1-ETO being detected in B cells.65,66 In summary, several approaches that mimic additional gene mutations in human t(8;21) AML or that counteract AML1-ETO-induced inhibition of cell cycle progression have been useful in generating AML1-ETO leukemic mouse models. More challenging will be to identify the molecular mechanisms of additional cytogenetic defects, such as loss or gain of specific chromosomes, associated with t(8;21) AML, because these losses and gains suggest the presence of possibly one or more tumor suppressors or amplified oncogenes.


   Transcribed isoforms of t(8;21) and their impact on leukemogenesis
Top
 Abstract
 Introduction
 Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
Future directions
 Authorship
 References
 
Besides the full-length AML1-ETO transcript, alternative AML1-ETO transcripts have been reported in t(8;21) patient samples and/or in leukemia cell lines with t(8;21). The predicted proteins of these alternative transcripts are shorter versions of the full-length AML1-ETO (Figure 2). Three AML1-ETO transcripts (runt/46nt/MTG8, runt/82nt/MTG8, and runt/68nt/MTG8) with insertions between exon 5 of AML1 and exon 2 of ETO have been detected in t(8;21) patient samples.67,68 These insertions cause AML1 to be out of frame with ETO and result in an in-frame stop codon before the ETO sequence. AML1-ETO transcripts containing intron 2, 4, or 5 of ETO were also reported by several groups.7,69,70 Reverse transcriptase (RT)-PCR studies showed that the ETO intron 4- and intron 5-containing transcripts coexisted with the full-length AML1-ETO in all t(8;21) patient samples tested.69,71 An AML1-ETO transcript with a 50-nucleotide deletion in exon 2 of ETO was reported as the only fusion transcript in one patient sample.72 This transcript is capable of generating an AML1-ETO protein that contains amino acids 1 to 184 of the full-length AML1-ETO and 24 additional amino acids (Figure 2). Alternate splicing of AML1 amino-terminal exons that exclude exons 2 and 3 has been reported.73 This could conceivably produce an AML1-ETO transcript with a substantial portion of the DNA-binding RHD deleted (Figure 2). However, AML1-ETO transcripts with this structure have not yet been detected. Furthermore, the alternatively spliced isoforms of AML1-ETO, AML1-ETO9a,74 and AML1-ETO11a,75 are coexpressed with full-length AML1-ETO in t(8;21) patient samples. Both of these transcripts generate C-terminal truncated AML1-ETO proteins (Figure 2). The detection of these shorter AML1-ETO transcripts in t(8;21) AML patients raises the question as to whether AML1 truncation per se or its fusion to ETO is crucial to leukemia development and whether fusion proteins derived from incompletely processed alternative transcripts or alternative spliced products contribute to leukemogenesis.


Figure 2
View larger version (41K):
[in this window]
[in a new window]

  		Figure 2. Other possible AML1-ETO fusion proteins from reported alternate transcripts. Shown are other known alternative AML1-ETO predicted gene products identified in cell lines and patient samples aligned to the full-length fusion protein. The vertical arrow points to the fusion junction between AML1 and ETO. RHD indicates runt homology domain; NHR1 to NLH4, Drosophila Nervy protein homology regions; and PST, proline-serine-threonine-rich regions. References identifying these alternative products are indicated.

 
In summary, these alternative AML1-ETO transcripts are capable of producing fusion proteins lacking either entire or various portions of the C-terminal ETO protein. In addition to the recent discovery of the AML1-ETO9a splice variant, which is addressed next, the question is raised as to whether various of these shorter AML1-ETO fusion proteins contribute to the development of leukemia in human t(8;21) patients in a cooperative manner.

A C-terminal truncated form of AML1-ETO (AML1-ETOtr) was found to cause leukemia.63 AML1-ETOtr was generated in vivo by a single-nucleotide insertion in the AML1-ETO DNA sequence, leading to the early termination of protein translation thereby lacking the NHR3 and NHR4 domains. This finding triggered the identification of the alternatively spliced AML1-ETO9a transcript in t(8;21) AML described in the paragraph above, which also leads to rapid leukemia development in mice.74 These results suggest that the C-terminal portion of ETO inhibits the leukemogenic potential of AML1-ETO. It is likely that one type of mutation that can promote AML1-ETO-induced leukemogenesis in mice is to directly or indirectly block the molecular events associated with the C terminus of AML1-ETO. Unlike their full-length counterpart, AML1-ETOtr and AML1-ETO9a did not have an inhibitory effect on myeloid cell cycle progression although they retained the ability to block myeloid cell differentiation.63,74 Moreover, coexpression of AML1-ETO and AML1-ETO9a results in an earlier onset of leukemia development, blocking myeloid cell differentiation at an earlier stage of hematopoiesis compared with the expression of AML1-ETO9a alone.74 This suggests that fusion proteins from various alternatively spliced transcripts of the 8;21 translocation may cooperate in promoting leukemogenesis.

It will be, however, interesting to solidify the contribution of the AML1-ETO9a splice variant to a prognostic value in patients, as observed with the prognosis value associated with c-KIT mutations in t(8;21).44,45—specifically, to see how the level of transcript determines the overall survival. As has been observed in t(12;21) childhood ALL cases, high expression of the reciprocal AML1-TEL fusion gene is an independent poor prognostic factor.76 Furthermore, expression of the splice variants of survivin, a member of the inhibitor of apoptosis protein family, survivin-2B and survivin-DeltaEx3, is valuable in prognosis in adult and childhood AML following treatment, respectively.77 In addition, it will be of interest to see if the AML1-ETO9a transcript is present during remission compared with full-length AML1-ETO. One scenario could be envisioned in which the loss of the AML1-ETO9a splice variant at remission and the continued presence of the full-length AML1-ETO transcript would suggest that the alternative splicing of the t(8;21) transcript is itself a secondary event involving posttranscriptional regulation. Furthermore, with the discovery of additional mutations in t(8;21) patients, the question remains if AML1-ETO9a is also present and to what level. These studies will help identify if AML1-ETO9a is truly a secondary deregulated posttranscriptional event that will promote leukemia in the absence of any other secondary mutagenic event or if it is one of the pieces of the puzzle in the complex regulation of AML1-ETO leukemogenesis. In addition, the question persists as to the contribution of the C-terminal region that is known to interact with the NCoR repressor protein.78,79 Specifically, does NCoR actually function as a "proteonomic" tumor suppressor in t(8;21)? This is interesting because NCoR is located on chromosome 17p11.2, which is often lost in various malignant tumors80 including AML/MDS patients.81 However, from the literature it is evident that the loss of chromosome 17 is not a common event in t(8;21) leukemia. Thus, the loss of the "proteonomic" pathway of NCoR may be a way forward in t(8;21)-associated leukemia with the loss of the NHR4 zinc finger domain in both AML1-ETO9a and AML1-ETO11a splice variants. Although NCoR should associate as well with the N-terminal region of both AML1-ETO9a and AML1-ETO11a, the loss of a protein complex involving the NHR4/NCoR and/or other interacting proteins like HDACs suggest that this NHR4/NCoR interaction is crucial for blocking the leukemogenic potential of AML1-ETO. Furthermore, recently it was shown that the NHR4 domain is also important in blocking p300 acetylation of GATA-1, inhibiting erythroid differentiation.82

Interestingly, a recent report describes how AML1-ETO9a and the mutant AML1-ETOtr are able to break through the mitotic arrest induced by various mitosis poisons causing aneuploidy.83 Next to the observation of AML1-ETO deregulating DNA repair genes84 that are important in genome stability, these observations demonstrate that AML1-ETO splice variant(s) may affect the normal mitotic checkpoint.83 It does this specifically by negatively targeting securin involved in regulating mitosis by preventing anaphase through its association with the separase protease, which is responsible for loss of sister chromatid cohesion through cleavage of the Scc1/hRad21 cohesin subunit.83 These observations support a potential model in which AML1-ETO and its splice variant(s) are the first event that is able to promote secondary mutagenic events promoting full-blown leukemia development and the associated gain and loss of chromosomal material.

These new developments suggest a new model of t(8;21) leukemogenesis in which stem cell renewal and loss of DNA repair ability caused by AML1-ETO drive the ideal condition for leukemia development, promoting secondary mutagenic events. Alternatively, deregulated splicing of AML1-ETO may lead to an alternate model in which the requirement of secondary mutations in other genes is not directly required. Thus, AML1-ETO9a may drive leukemia development in cooperation with AML1-ETO, in addition to gain and loss of genomic material (Figure 3). The discovery of AML1-ETO9a, which promotes leukemia development on its own or in cooperation with AML1-ETO, points to the importance of not just understanding full-length AML1-ETO but to the need to also better understand its splice variant(s). The cooperative leukemogenesis with the combined AML1-ETO and AML1-ETO9a expression highlights that t(8;21) may follow a mechanism of leukemogenesis in the footsteps of some other known oncogenes, such as HER2,85 cyclin D1,86,87 and TRKA,88 that display increased transformation activity observed with the splice isoforms {Delta}HER2, cyclin D1b, and TRKA-III, respectively. Although it is known that full-length ETO protein is expressed in hematopoietic cells, it still has to be confirmed that splicing of exon 9a occurs in these cells and, more specifically, in which differentiated cells it happens. This as the expression of ETO in human myeloid cells is very low compared with its family members MTG16 and MTGR1,89 in agreement with AML1-ETO blocking granulocytic differentiation by sequestering NCoR from MTG16.90 The ability of ETO9a generation by normal splicing events also opens the can of worms as to whether the AML1-ETO9a spliced form is expressed before or after leukemia development. This is because varying levels of AML1-ETO9a are observed in t(8;21) patients74 in addition to patients in remission still containing AML1-ETO-positive cells.65,67 Thus, the possibility of deregulated alternative processing of AML1-ETO mRNA being required for transformation is brought forth, as is seen in the case of the receptor tyrosine phosphatase PTPN6, which undergoes RNA editing and alternative splicing leading to the production of an inactive protein unable to block receptor tyrosine kinases like c-KIT, providing ideal conditions for leukemia development.91 Moreover, the phenomenon of deregulated splicing events as a mechanism of cancer development is evident by observations of altered RNA processing of tumor suppressors and oncogenes (reviewed by Kalnina et al92 and Scholzova et al93). The presence of alternative splice forms of fusion genes is not uncommon, because the MLL-AF4 fusion gene expresses various splice variants due to the presence of cryptic splice sites94; however, direct evidence for a role of these alternative transcripts in leukemogenesis has not been presented as yet. There is further evidence of BCR-ABL signaling deregulating the splicing of the Ikaros gene in t(9;22) pre-B-cell leukemia.95 In addition, that BCR-ABLp210 is able to induce the expression of various splicing factors in primary human CD34+ hematopoietic progenitor cells deregulating splicing of the PYK2 gene.96 Thus, the identification of alternative splicing of AML1-ETO in patient samples and the cooperative mouse model of AML1-ETO/AML1-ETO9a leukemogenesis show that not all has been learned in mechanisms of transformation by the 8;21 translocation.


Figure 3
View larger version (34K):
[in this window]
[in a new window]

  		Figure 3. Diagram of the multistep leukemogenesis process associated with t(8;21). This model shows that after the initial event of t(8;21) within the hematopoietic stem cells (HSC) or multipotential progenitor (MPP), the cells will initially expand by the stem cell renewal program induced by the AML1-ETO fusion proteins associated with a block in myeloid differentiation. The loss of DNA repair mechanisms elicited by AML1-ETO creates an ideal environment for the acquisition of additional transforming mutagenic events such as FLT3 and Ras or deregulation of the NCoR/SMRT pathway. However, the appearance of alternative splice variants such as AML1-ETO9a may contribute to the speed of transformation or may even cooperate with AML1-ETO, being itself a secondary event by deregulated alternative splicing. The expression of AML1-ETO isoforms may also further aid in the gain and/or loss of genomic material often observed in t(8;21) leukemia through the deregulation of the mitotic checkpoint.

 
Thus, AML1-ETO alternative splicing leading to the loss of the interaction of C-terminal portion of AML1-ETO with other proteins is one possible route of leukemogenesis by t(8;21). Alternatively, loss of function or binding of proteins interacting with C-terminal portion of AML1-ETO or their further downstream pathways is another possible mechanism of leukemogenesis by t(8;21). Next to interacting with NCoR, the NHR4 domain of AML1-ETO or ETO also interacts with the silencing mediator of retinoic acid and thyroid hormone receptor (SMRT).78,79 Further, there is tangible evidence of SMRT functional tumor suppressive role in non-Hodgkin lymphoma in a haploinsufficient manner.97 Specifically, the SMRT gene located at chromosome 12q24 is often abrogated by chromosomal rearrangements, decreasing its transcript and protein levels in cell lines and primary patient lymphoma samples. This chromosome 12q24 region is also implicated in AML.98–100 Further down-regulation of SMRT by antisense strategy conferred transformation of fibroblasts in cooperation with overexpressed hTert (telomerase) and SV40-LargeT in soft-agar assays. In addition, reconstitution in lymphoma cell lines with exogenous SMRT expression induced apoptosis.97 Furthermore, the presence of the FLT3-internal tandem duplication mutant in AML is able to block SMRT-specific regulation of PLZF growth inhibitory action.101 Thus, bypass of the tumor suppressive roles of either NCoR or SMRT pathways associated with the C terminus of AML1-ETO by mutagenic events is a putative mechanism of leukemogenesis involving t(8;21) and requires further investigation.


   Future directions
Top
 Abstract
 Introduction
 Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
 Future directions
Authorship
 References
 
Although AML1-ETO9a is a potent inducer of leukemia in mice, AML1-ETO9a mutants that are unable to bind to DNA are not leukemogenic (M.Y., D.-E.Z., unpublished data, February 2005). This result in addition to previous studies suggests that the DNA-binding domain of t(8;21) fusion proteins is important in directing the expression of certain important genes that control cell proliferation, differentiation, and survival. Thus, further studies to elucidate the complex mechanism of t(8;21) leukemogenesis should address issues such as (1) the clinical significance of the expression levels of alternatively spliced AML1-ETO isoforms, (2) the function of the AML1-ETO/alternatively spliced AML1-ETO heterodimers/homodimers, (3) the mechanism of regulated AML1-ETO splicing, (4) localization, (5) deregulated gene expression in the presence or absence of the splice variants and the analysis of newly identified potential targets on their specific roles in leukemia development, and (6) and altered or enhanced protein-protein interactions due to the presence of splice variants.

Future development of therapeutic regimens to effectively target the AML1-ETO fusion protein(s), such as decreasing its RNA or protein stability, preventing its binding to DNA and cofactors, and altering its cellular localization, should be valuable approaches against t(8;21) leukemogenesis. The generation of various mouse models described above further form ideal primary models, as exemplified by the use of AML1-ETOtr in testing a new drug and combinations of drugs102,103 and testing the new generations ofchemotherapeutics and/or alternative molecular biologic approaches for treating t(8;21) leukemia.


   Authorship
Top
 Abstract
 Introduction
 Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
 Future directions
 Authorship
References
 
Contribution: All authors contributed to writing this review.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dong-Er Zhang, MEM-L51, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037; e-mail: dzhang{at}scripps.edu.


   Acknowledgments
 
This work was supported by grants from the National Institutes of Health, National Cancer Institute (CA96735 and CA104509). We apologize to all researchers whose relevant work could not be cited due to space limitations.


   Footnotes
 
Submitted November 10, 2006; accepted March 25, 2007.

Prepublished online as Blood First Edition Paper, April 5, 2007 DOI: 10.1182/blood-2006-11-019265


   References
Top
 Abstract
 Introduction
 Additional mutations and mouse...
 Transcribed isoforms of t(8;21)...
 Future directions
 Authorship
 References
 

  1. Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16:109–112.[Medline] [Order article via Infotrieve]

  2. Groupe Français de Cytogénétique Hématologique. Acute myelogenous leukemia with an 8;21translocation. A report on 148 cases from the Groupe Francais de Cytogenetique Hematologique. Cancer Genet Cytogenet 1990; 44:169–179.[CrossRef][Medline] [Order article via Infotrieve]

  3. Lai YY, Qiu JY, Jiang B, et al. Characteristics and prognostic factors of acute myeloid leukemia with t (8; 21) (q22; q22). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005; 13:733–740.[Medline] [Order article via Infotrieve]

  4. Miyoshi H, Shimizu K, Kozu T, et al. t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc Natl Acad Sci U S A 1991; 88:10431–10434.[Abstract/Free Full Text]

  5. Erickson P, Gao J, Chang KS, et al. Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood 1992; 80:1825–1831.[Abstract/Free Full Text]

  6. van Wijnen AJ, Stein GS, Gergen JP, et al. Nomenclature for Runt-related (RUNX) proteins. Oncogene 2004; 23:4209–4210.[CrossRef][Medline] [Order article via Infotrieve]

  7. Nisson PE, Watkins PC, Sacchi N. Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. Cancer Genet Cytogenet 1992; 63:81–88.[CrossRef][Medline] [Order article via Infotrieve]

  8. Miyoshi H, Kozu T, Shimizu K, et al. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 1993; 12:2715–2721.[Medline] [Order article via Infotrieve]

  9. Licht JD. AML1 and the AML1-ETO fusion protein in the pathogenesis of t(8;21) AML. Oncogene 2001; 20:5660–5679.[CrossRef][Medline] [Order article via Infotrieve]

  10. Erickson PF, Dessev G, Lasher RS, et al. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood 1996; 88:1813–1823.[Abstract/Free Full Text]

  11. Liu Y, Cheney MD, Gaudet JJ, et al. The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell 2006; 9:249–260.[CrossRef][Medline] [Order article via Infotrieve]

  12. Ghozi MC, Bernstein Y, Negreanu V, Levanon D, Groner Y. Expression of the human acute myeloid leukemia gene AML1 is regulated by two promoter regions. Proc Natl Acad Sci U S A 1996; 93:1935–1940.[Abstract/Free Full Text]

  13. Levanon D and Groner Y. Structure and regulated expression of mammalian RUNX genes. Oncogene 2004; 23:4211–4219.[CrossRef][Medline] [Order article via Infotrieve]

  14. Fujita Y, Nishimura M, Taniwaki M, Abe T, Okuda T. Identification of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early hematopoietic development. Biochem Biophys Res Commun 2001; 281:1248–1255.[CrossRef][Medline] [Order article via Infotrieve]

  15. Telfer JC and Rothenberg EV. Expression and function of a stem cell promoter for the murine CBFalpha2 gene: distinct roles and regulation in natural killer and T cell development. Dev Biol 2001; 229:363–382.[CrossRef][Medline] [Order article via Infotrieve]

  16. Peterson LF and Zhang DE. The 8;21 translocation in leukemogenesis. Oncogene 2004; 23:4255–4262.[CrossRef][Medline] [Order article via Infotrieve]

  17. Elagib KE and Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett 2007; 251:179–186.[CrossRef][Medline] [Order article via Infotrieve]

  18. Choi Y, Elagib KE, Goldfarb AN. AML-1-ETO-mediated erythroid inhibition: new paradigms for differentiation blockade by a leukemic fusion protein. Crit Rev Eukaryot Gene Expr 2005; 15:207–216.[Medline] [Order article via Infotrieve]

  19. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet 1997; 15:303–306.[CrossRef][Medline] [Order article via Infotrieve]

  20. Okuda T, Cai Z, Yang S, et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 1998; 91:3134–3143.[Abstract/Free Full Text]

  21. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84:321–330.[CrossRef][Medline] [Order article via Infotrieve]

  22. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell 1996; 87:697–708.[CrossRef][Medline] [Order article via Infotrieve]

  23. Rhoades KL, Hetherington CJ, Harakawa N, et al. Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model. Blood 2000; 96:2108–2115.[Abstract/Free Full Text]

  24. Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 2001; 98:10398–10403.[Abstract/Free Full Text]

  25. Fenske TS, Pengue G, Mathews V, et al. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc Natl Acad Sci U S A 2004; 101:15184–15189.[Abstract/Free Full Text]

  26. Buchholz F, Refaeli Y, Trumpp A, Bishop JM. Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep 2000; 1:133–139.[CrossRef][Medline] [Order article via Infotrieve]

  27. Higuchi M, O'Brien D, Kumaravelu P, et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1:63–74.[CrossRef][Medline] [Order article via Infotrieve]

  28. de Guzman CG, Warren AJ, Zhang Z, et al. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 2002; 22:5506–5517.[Abstract/Free Full Text]

  29. Schwieger M, Lohler J, Friel J, et al. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med 2002; 196:1227–1240.[Abstract/Free Full Text]

  30. Sakurai M, Oshimura M, Kakati S, Sandberg AA. Letter: 8-21 translocation and missing sex chromosomes in acute leukaemia. Lancet 1974; 2:227–228.[Medline] [Order article via Infotrieve]

  31. Johansson B, Mertens F, Mitelman F. Secondary chromosomal abnormalities in acute leukemias. Leukemia 1994; 8:953–962.[Medline] [Order article via Infotrieve]

  32. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006; 135:165–173.[CrossRef][Medline] [Order article via Infotrieve]

  33. Chen FJ, Yang AD, Fei HB. A chromosome study on 97 cases of acute nonlymphocytic leukemia M2. J Tongji Med Univ 1994; 14:35–37.[Medline] [Order article via Infotrieve]

  34. Heim S and Mitelman F. Secondary chromosome aberrations in the acute leukemias. Cancer Genet Cytogenet 1986; 22:331–338.[CrossRef][Medline] [Order article via Infotrieve]

  35. Herens C, Brasseur E, Jamar M, et al. Loss of the Y chromosome in bone marrow cells: results on 1907 consecutive cases of leukaemia and preleukaemia. Clin Lab Haematol 1999; 21:17–20.[CrossRef][Medline] [Order article via Infotrieve]

  36. Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134:616–619.[CrossRef][Medline] [Order article via Infotrieve]

  37. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004; 22:3741–3750.[Abstract/Free Full Text]

  38. Schessl C, Rawat VP, Cusan M, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005; 115:2159–2168.[CrossRef][Medline] [Order article via Infotrieve]

  39. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98:1752–1759.[Abstract/Free Full Text]

  40. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100:59–66.[Abstract/Free Full Text]

  41. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001; 97:2434–2439.[Abstract/Free Full Text]

  42. Lasa A, Carricondo MT, Carnicer MJ, et al. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia. Haematologica 2006; 91:1283–1284.[Abstract/Free Full Text]

  43. Nanri T, Matsuno N, Kawakita T, et al. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). Leukemia 2005; 19:1361–1366.[CrossRef][Medline] [Order article via Infotrieve]

  44. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107:3463–3468.[Abstract/Free Full Text]

  45. Schnittger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO positive AML are associated with impaired event-free and overall survival. Blood 2005; 107:1791–1799.[CrossRef][Medline] [Order article via Infotrieve]

  46. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci U S A 2005; 102:1104–1109.[Abstract/Free Full Text]

  47. Bacher U, Haferlach T, Schoch C, Kern W, Schnittger S. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006; 107:3847–3853.[Abstract/Free Full Text]

  48. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005; 106:2113–2119.[Abstract/Free Full Text]

  49. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93:3074–3080.[Abstract/Free Full Text]

  50. Mertens F, Johansson B, Mitelman F. Age- and gender-related heterogeneity of cancer chromosome aberrations. Cancer Genet Cytogenet 1993; 70:6–11.[CrossRef][Medline] [Order article via Infotrieve]

  51. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77:307–316.[CrossRef][Medline] [Order article via Infotrieve]

  52. Kojima K, Yasukawa M, Ishimaru F, et al. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase. Br J Haematol 1999; 106:720–722.[CrossRef][Medline] [Order article via Infotrieve]

  53. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473–481.[Abstract/Free Full Text]

  54. von Bubnoff N, Gorantla SHP, Kancha RK, et al. The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107. Leukemia 2005; 19:1670–1671.[CrossRef][Medline] [Order article via Infotrieve]

  55. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107:752–759.[Abstract/Free Full Text]

  56. Bali P, George P, Cohen P, et al. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 2004; 10:4991–4997.[Abstract/Free Full Text]

  57. George P, Bali P, Cohen P, et al. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 2004; 64:3645–3652.[Abstract/Free Full Text]

  58. Seedhouse CH, Hunter HM, Lloyd-Lewis B, et al. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 2006; 20:2130–2136.[CrossRef][Medline] [Order article via Infotrieve]

  59. Schittenhelm MM, Yee KWH, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to sunitinib (SU11248). Leukemia 2006; 20:2008–2014.[CrossRef][Medline] [Order article via Infotrieve]

  60. Ikezoe T, Nishioka C, Tasaka T, et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 2006; 5:2522–2530.[Abstract/Free Full Text]

  61. Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A 2003; 100:9506–9511.[Abstract/Free Full Text]

  62. Nishida S, Hosen N, Shirakata T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with Wilms' tumor gene, WT1. Blood 2005; 107:3303–3312.[Medline] [Order article via Infotrieve]

  63. Yan M, Burel SA, Peterson LF, et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A 2004; 101:17186–17191.[Abstract/Free Full Text]

  64. Peterson LF, Yan Ming, Zhang DE. The p21waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood 2007; 109:4392–4398.[Abstract/Free Full Text]

  65. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci U S A 2000; 97:7521–7526.[Abstract/Free Full Text]

  66. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87:4789–4796.[Abstract/Free Full Text]

  67. Tighe JE and Calabi F. Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 1994; 84:2115–2121.[Abstract/Free Full Text]

  68. van de Locht LT, Smetsers TF, Wittebol S, Raymakers RA, Mensink EJ. Molecular diversity in AML1/ETO fusion transcripts in patients with t(8;21) positive acute myeloid leukaemia. Leukemia 1994; 8:1780–1784.[Medline] [Order article via Infotrieve]

  69. Kozu T, Miyoshi H, Shimizu K, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993; 82:1270–1276.[Abstract/Free Full Text]

  70. Era T, Asou N, Kunisada T, et al. Identification of two transcripts of AML1/ETO-fused gene in t(8;21) leukemic cells and expression of wild-type ETO gene in hematopoietic cells. Genes Chromosomes Cancer 1995; 13:25–33.[Medline] [Order article via Infotrieve]

  71. Era T, Asou N, Yamaguchi K, et al. Expression of AML1 and ETO transcripts in hematopoietic cells. Leukemia 1995; 9:suppl 1, S26–S28.[Medline] [Order article via Infotrieve]

  72. Lasa A, Nomdedeu JF, Carnicer MJ, Llorente A, Sierra J. ETO sequence may be dispensable in some AML1-ETO leukemias. Blood 2002; 100:4243–4244.[Free Full Text]

  73. Zhang YW, Bae SC, Huang G, et al. A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol 1997; 17:4133–4145.[Abstract]

  74. Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12:945–949.[CrossRef][Medline] [Order article via Infotrieve]

  75. Kozu T, Fukuyama T, Yamami T, Akagi K, Kaneko Y. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21). Genes Chromosomes Cancer 2005; 43:45–53.[CrossRef][Medline] [Order article via Infotrieve]

  76. Stams WAG, den Boer ML, Beverloo HB, et al. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia. Clin Cancer Res 2005; 11:2974–2980.[Abstract/Free Full Text]

  77. Wagner M, Schmelz K, Wuchter C, et al. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer 2006; 119:1291–1297.[CrossRef][Medline] [Order article via Infotrieve]

  78. Gelmetti V, Zhang J, Fanelli M, et al. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 1998; 18:7185–7191.[Abstract/Free Full Text]

  79. Zhang J, Hug BA, Huang EY, et al. Oligomerization of ETO is obligatory for corepressor interaction. Mol Cell Biol 2001; 21:156–163.[Abstract/Free Full Text]

  80. Stacey MW, Wang J, Byrd RL, Liu JM, Kearns WG. Nuclear receptor co-repressor gene localizes to 17p11.2, a frequently deleted band in malignant disorders. Genes Chromosomes Cancer 1999; 25:191–193.[CrossRef][Medline] [Order article via Infotrieve]

  81. Soenen V, Preudhomme C, Roumier C, et al. 17p deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood 1998; 91:1008–1015.[Abstract/Free Full Text]

  82. Choi Y, Elagib KE, Delehanty LL, Goldfarb AN. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1. Cancer Res 2006; 66:2990–2996.[Abstract/Free Full Text]

  83. Boyapati A, Yan M, Peterson LF, et al. A leukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy. Blood 2007; 109:3963–3971.[Abstract/Free Full Text]

  84. Alcalay M, Meani N, Gelmetti V, et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112:1751–1761.[CrossRef][Medline] [Order article via Infotrieve]

  85. Kwong KY and Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998; 23:62–68.[CrossRef][Medline] [Order article via Infotrieve]

  86. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants: differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003; 278:30339–30347.[Abstract/Free Full Text]

  87. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003; 63:7056–7061.[Abstract/Free Full Text]

  88. Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004; 6:347–360.[CrossRef][Medline] [Order article via Infotrieve]

  89. Lindberg SR, Olsson A, Persson AM, Olsson I. The leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation. Exp Hematol 2005; 33:189–198.[CrossRef][Medline] [Order article via Infotrieve]

  90. Ibanez V, Sharma A, Buonamici S, et al. AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation. Cancer Res 2004; 64:4547–4554.[Abstract/Free Full Text]

  91. Beghini A, Ripamonti CB, Peterlongo P, et al. RNA hyperediting and alternative splicing of hematopoietic cell phosphatase (PTPN6) gene in acute myeloid leukemia. Hum Mol Genet 2000; 9:2297–2304.[Abstract/Free Full Text]

  92. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005; 42:342–357.[CrossRef][Medline] [Order article via Infotrieve]

  93. Scholzova E, Malik R, Sevcik J, Kleibl Z. RNA regulation and cancer development. Cancer Lett 2007; 246:12–23.[CrossRef][Medline] [Order article via Infotrieve]

  94. Divoky V, Trka JM, Watzinger F, Lion T. Cryptic splice site activation during RNA processing of MLL/AF4 chimeric transcripts in infants with t(4;11) positive ALL. Gene 2000; 247:111–118.[CrossRef][Medline] [Order article via Infotrieve]

  95. Klein F, Feldhahn N, Herzog S, et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2005; 25:1118–1124.[CrossRef]

  96. Salesse S, Dylla SJ, Verfaillie CM. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia 2004; 18:727–733.[CrossRef][Medline] [Order article via Infotrieve]

  97. Song L, Zlobin A, Ghoshal P, et al. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res 2005; 65:4554–4561.[Abstract/Free Full Text]

  98. Yamagata N, Shimazaki C, Kikuta T, et al. A translocation between 3q21 and 12q24 in a patient with minimally differentiated acute myeloid leukemia (AML-MO). Cancer Genet Cytogenet 1997; 97:90–93.[CrossRef][Medline] [Order article via Infotrieve]

  99. Roulston D, Espinosa R III, Nucifora G, et al. CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 1998; 92:2879–2885.[Abstract/Free Full Text]

  100. Cox MC, Scanzani A, Del Poeta G, et al. A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0). Cancer Genet Cytogenet 2000; 118:29–79.

  101. Takahashi S, McConnell MJ, Harigae H, et al. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood 2004; 103:4650–4658.

  102. Wang L, Zhao WL, Yan JS, et al. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 2007; 14:306–317.[CrossRef][Medline] [Order article via Infotrieve]

  103. Zhou GB, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007; 109:3441–3450.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
C. Guo, Q. Hu, C. Yan, and J. Zhang
Multivalent Binding of the ETO Corepressor to E Proteins Facilitates Dual Repression Controls Targeting Chromatin and the Basal Transcription Machinery
Mol. Cell. Biol., May 15, 2009; 29(10): 2644 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
S. A. Gustafson, P. Lin, S. S. Chen, L. Chen, L. V. Abruzzo, R. Luthra, L. J. Medeiros, and S. A. Wang
Therapy-Related Acute Myeloid Leukemia With t(8;21) (q22;q22) Shares Many Features With De Novo Acute Myeloid Leukemia With t(8;21)(q22;q22) but Does Not Have a Favorable Outcome
Am J Clin Pathol, May 1, 2009; 131(5): 647 - 655.
[Abstract] [Full Text] [PDF]

Home page
 Arch Otolaryngol Head Neck SurgHome page
I. M. Smith, S. K. Mithani, C. Liu, S. S. Chang, S. Begum, M. Dhara, W. Westra, D. Sidranksy, and J. A. Califano
Novel Integrative Methods for Gene Discovery Associated With Head and Neck Squamous Cell Carcinoma Development
Arch Otolaryngol Head Neck Surg, May 1, 2009; 135(5): 487 - 495.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Kuwatsuka, K. Miyamura, R. Suzuki, M. Kasai, A. Maruta, H. Ogawa, R. Tanosaki, S. Takahashi, K. Koda, K. Yago, et al.
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Blood, February 26, 2009; 113(9): 2096 - 2103.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Yan, E.-Y. Ahn, S. W. Hiebert, and D.-E. Zhang
RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis
Blood, January 22, 2009; 113(4): 883 - 886.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. J. Okumura, L. F. Peterson, F. Okumura, A. Boyapati, and D.-E. Zhang
t(8;21)(q22;q22) fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression
Blood, August 15, 2008; 112(4): 1392 - 1401.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. Pedersen-Bjergaard, M. T. Andersen, and M. K. Andersen
Genetic Pathways in the Pathogenesis of Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Hematology, January 1, 2007; 2007(1): 392 - 397.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-11-019265v1
110/3/799    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Peterson, L. F.
Right arrow Articles by Zhang, D.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peterson, L. F.
Right arrow Articles by Zhang, D.-E.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020